TY - JOUR
T1 - Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report
T2 - GOLD Executive Summary
AU - Vogelmeier, Claus F.
AU - Criner, Gerard J.
AU - Martinez, Fernando J.
AU - Anzueto, Antonio
AU - Barnes, Peter J.
AU - Bourbeau, Jean
AU - Celli, Bartolome R.
AU - Chen, Rongchang
AU - Decramer, Marc
AU - Fabbri, Leonardo M.
AU - Frith, Peter
AU - Halpin, David M.G.
AU - Varela, M. Victorina López
AU - Nishimura, Masaharu
AU - Roche, Nicolas
AU - Rodriguez-Roisin, Roberto
AU - Sin, Don D.
AU - Singh, Dave
AU - Stockley, Robert
AU - Vestbo, Jørgen
AU - Wedzicha, Jadwiga A.
AU - Agustí, Alvar
PY - 2017/3/1
Y1 - 2017/3/1
N2 - This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 report focuses primarily on the revised and novel parts of the document. The most significant changes include: (1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; (2) for each of the groups A to D, escalation strategies for pharmacologic treatments are proposed; (3) the concept of deescalation of therapy is introduced in the treatment assessment scheme; (4) nonpharmacologic therapies are comprehensively presented; and (5) the importance of comorbid conditions in managing chronic obstructive pulmonary disease is reviewed.
AB - This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 report focuses primarily on the revised and novel parts of the document. The most significant changes include: (1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; (2) for each of the groups A to D, escalation strategies for pharmacologic treatments are proposed; (3) the concept of deescalation of therapy is introduced in the treatment assessment scheme; (4) nonpharmacologic therapies are comprehensively presented; and (5) the importance of comorbid conditions in managing chronic obstructive pulmonary disease is reviewed.
KW - Chronic obstructive pulmonary disease
KW - COPD diagnosis
KW - COPD management
KW - COPD prevention
UR - http://www.scopus.com/inward/record.url?scp=85014789444&partnerID=8YFLogxK
U2 - 10.1164/rccm.201701-0218PP
DO - 10.1164/rccm.201701-0218PP
M3 - Review article
C2 - 28128970
AN - SCOPUS:85014789444
SN - 1073-449X
VL - 195
SP - 557
EP - 582
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 5
ER -